A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapies. The team is also developing an algorithm to predict...
Researchers from the University of Oslo and Roche 's Genentech Inc. unit have developed several selective inhibitors of tankyrases TNKS and TNKS2 , two druggable targets in the otherwise hard-to-hit WNT pathway. 1,2 The University team's...
...2006. But beyond the clinical diagnostics space, the company wants to be a player in predictive diagnostics... ...and doctor decide what to do about it. There’s a broader and deeper market for predictive diagnostics."... ...want to have the test at a much earlier age." Technically speaking, he added, developing predictive diagnostics...
A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapies. The team is also developing an algorithm to predict...
Researchers from the University of Oslo and Roche 's Genentech Inc. unit have developed several selective inhibitors of tankyrases TNKS and TNKS2 , two druggable targets in the otherwise hard-to-hit WNT pathway. 1,2 The University team's...
...2006. But beyond the clinical diagnostics space, the company wants to be a player in predictive diagnostics... ...and doctor decide what to do about it. There’s a broader and deeper market for predictive diagnostics."... ...want to have the test at a much earlier age." Technically speaking, he added, developing predictive diagnostics...
